Abstract
Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Current Neuropharmacology
Title: Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Volume: 3 Issue: 4
Author(s): Y. Zhang and H. K. Kimelberg
Affiliation:
Keywords: alpha -adrenergic agonist, adrenoceptor, imidazoline receptor, cerebral ischemia, neuroprotection, excitatory amino acids, sympathoinhibition, stroke
Abstract: Ischemic brain injury is implicated in the pathophysiology of stroke and brain trauma, which are among the top killers worldwide, and intensive studies have been performed to reduce neural cell death after cerebral ischemia. Alpha 2- adrenergic agonists have been shown to improve the histomorphological and neurological outcome after cerebral ischemic injury when administered during ischemia, and recent studies have provided considerable evidence that alpha 2-adrenergic agonists can protect the brain from ischemia/reperfusion injury. Thus, alpha 2-adrenergic agonists are promising potential drugs in preventing cerebral ischemic injury, but the mechanisms by which alpha 2-adrenergic agonists exert their neuroprotective effect are unclear. Activation of both the alpha 2-adrenergic receptor and imidazoline receptor may be involved. This mini review examines the recent progress in alpha 2-adrenergic agonists - induced neuroprotection and its proposed mechanisms in cerebral ischemic injury.
Export Options
About this article
Cite this article as:
Zhang Y. and Kimelberg K. H., Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia, Current Neuropharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157015905774322534
DOI https://dx.doi.org/10.2174/157015905774322534 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Models for the Study of Angiogenesis
Current Pharmaceutical Design MicroRNAs in the Blood-Brain Barrier in Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Cell-Selective Mitochondrial Targeting: Progress in Mitochondrial Medicine
Current Drug Delivery The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters The Potential Protective Effect of Orange Peel and Selenium against 17β-Estradiol- Induced Chronic Non-Bacterial Prostatitis in Rats
Anti-Cancer Agents in Medicinal Chemistry Animal Models of Focal Cerebral Ischaemia and Haemorrhagic Transformation: Considerations in Experimental Stroke Study Design
Current Vascular Pharmacology Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Polysaccharide-Based Nanobiomaterials as Controlled Release Systems for Tissue Engineering Applications
Current Pharmaceutical Design Gas Bioengineering Using Hemoglobin-Vesicles For Versatile Clinical Applications
Current Pharmaceutical Design Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Resveratrol Protects Endothelial Cells from Rapid Stretch Injury and Hypoxia In Vitro
Current Drug Therapy Modulation of Neutrophil Development and Homeostasis
Current Molecular Medicine DNA Repair Proteins as Molecular Therapeutics for Oxidative and Alkylating Lung Injury
Current Gene Therapy